IGF-1 LR3

IGF-1 LR3 (also known as Insulin-like Growth Factor 1 Long R3) is a prominently researched experimental compound classified strictly within the Growth Factor framework. Operating primarily through advanced pharmacological pathways, it functions by iGF-1 analog with extended half-life for muscle cell hyperplasia (new cell creation, not just hypertrophy). Promotes nitrogen retention and protein synthesis. with a documented biological half-life of roughly 20 hours, in preclinical investigative trials and independent academic studies, researchers utilizing IGF-1 LR3 have documented significant, quantifiable biological outcomes, primarily focusing on muscle growth, recovery, hyperplasia. Typical research protocols investigate administering 50 to 50mcg via subq pathways 5x/wk. However, it is critically important to understand that while IGF-1 LR3 demonstrates profound physiological potential in highly controlled laboratory settings, it remains classified strictly as a research chemical and has not been approved by the United States Food and Drug Administration (FDA) for human therapeutic, diagnostic, or dietary consumption. Independent chemical analysis via rigorous third-party Certificate of Analysis (COA) testing utilizing High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS) remains the industry gold standard for verifying its base elemental stability when reconstituted appropriately in sterile bacteriostatic water.